Skip to main content
. 2016 Apr 8;7(40):64766–64777. doi: 10.18632/oncotarget.8649

Figure 4. Pharmacological inhibition of COX-2 enzyme activity resensitizes DiFi5 cells to cetuximab via induction of apoptosis.

Figure 4

(A and B) DiFi5 cells were treated with cetuximab (20 nM), celecoxib (20 μM), SC-236 (20 μM), and NS-398 (100 μM) alone or in combination as indicated for 24 h. Cell lysates were subjected to Western blotting analysis using the indicated antibodies (A) and subjected to flow cytometry analysis after staining with FITC-labeled Annexin V (B). In B, plots at left show individual comparisons for the sum of Q2 (late apoptotic cells) and Q3 (early apoptotic cells) derived from the contour plots shown at the right. Unpaired Student t test was performed. *p < 0.05; ns, not significant. Plots at right are FITC-Annexin V versus propidium iodide contour plots with quadrant gates showing four populations of DiFi5 cells untreated or treated as indicated.